Mental Disorders

Salivary Cortisol Patterns May Indicate Cognitive Aging

Older adults with higher cumulative daily cortisol levels experienced faster cognitive decline, while healthier day-to-day cortisol variability was linked to slower decline, suggesting that salivary cortisol may serve as an early biomarker of cognitive aging, although it was not associated with short-term Alzheimer’s disease (AD) risk. In this US prospective cohort study of 3,895 Black and White older adults (mean age 76.7 years) followed for up to 11 years, all measures of salivary cortisol were associated with cognitive performance at baseline. Longitudinally, participants with the highest cumulative cortisol exposure showed faster cognitive decline, whereas those with moderate to high intraday cortisol variability experienced slower decline. Measures of diurnal cortisol change, including the daily cortisol slope, were not associated with cognitive decline or incident AD. Black participants had lower overall cortisol exposure but flatter daily cortisol rhythms and lower intraday variability, indicating a more blunted cortisol pattern, although the relationship between cortisol and cognitive decline was similar across Black and White participants. These findings suggest that altered daily cortisol regulation is linked to neurocognitive aging and that racial differences in cortisol patterns may reflect the long-term biological effects of chronic stress and structural inequities. Source: https://jamanetwork.com/

hyangiu

Recent Posts

Intensive BP Control Reduces Cardiovascular Events After Ischemic Stroke

Targeting a systolic blood pressure (BP) of less than 120 mm Hg lowered the incidence…

20 hours ago

No Significant Reduction in Major Cardiovascular Events with Intensive BP Lowering in T2D

In patients with type 2 diabetes (T2D) and high cardiovascular risk, targeting a systolic blood…

20 hours ago

Stopping Statins Noninferior to Continuing Them in Older Adults without Known CVD

Among older adults with at least two chronic conditions but no known cardiovascular disease, discontinuing…

22 hours ago

Ziltivekimab and Pelacarsen Show No Clinical Benefit Despite Effective Biomarker Lowering

Two randomized, placebo-controlled trials of targeted therapies—ziltivekimab, a monoclonal antibody neutralizing interleukin-6, and pelacarsen, an…

2 days ago

Cold Drives Heart Failure Hospitalizations in Older US Adults

Among US Medicare beneficiaries, colder ambient temperatures were associated with increased heart failure hospitalizations while…

6 days ago

No Significant Difference Between Initial CTO-PCI and No CTO-PCI Strategies in 10-Year Follow-Up

In the 10-year extended follow-up of the DECISION-CTO trial, an initial strategy of percutaneous coronary…

6 days ago

This website uses cookies.